search
Back to results

ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

Primary Purpose

Fasciitis, Plantar

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ReNu Injection
Corticosteroid Injection
Sponsored by
NuTech Medical, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fasciitis, Plantar focused on measuring Plantar Fasciitis, Jogger's Heel, ReNu

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Ages 18 to 75 inclusive
  2. BMI less than 40
  3. Actively practicing a contraception method, abstinent, surgically sterile, or post-menopausal (defined as no menses for a minimum of 12 months)
  4. Reporting heel pain of >6 on a verbally administered 1-10 pain scale where 1 is no pain and 10 is extreme pain
  5. Diagnosed with plantar fasciitis in either foot
  6. Completed a minimum of two months of conservative, non-injection treatment/therapies (i.e., activity modification, icing, NSAIDs, orthotics, physical therapy, etc.)

Exclusion Criteria

  1. Prior surgery on the affected foot
  2. Prior injection treatment for plantar fasciitis within the past 6 months with steroids or tissue engineered materials just in the site seeking treatment
  3. Clinical signs and symptoms of infection of foot in question
  4. Evidence of significant neurological disease of either foot
  5. Non-ambulatory
  6. Presence of comorbidities that can be confused with or can exacerbate the condition including, but not limited to the following:

    • Calcaneal stress fracture
    • Nerve entrapment syndrome, such as Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome
    • Plantar Fascial rupture
    • Systemic disorders associated with enthesiopathy, i.e., Gout, Reiter's syndrome, rheumatoid arthritis, etc.
    • Achilles tendonitis
    • Fat Pad Atrophy
    • Fibromyalgia
    • Diabetic Neuropathy
  7. Pregnant, pregnant within the past six (6) months, breast feeding and/or desire to become pregnant during the course of the study, as verified by urine pregnancy test within one week prior to injection.
  8. Has taken NSAID medication within the past 14 days, or other pain medication in the past day
  9. History of more than two (2) weeks treatment with immuno-suppressants, including systemic corticosteroids or cytotoxic chemotherapy within one month prior to initial screening, or has receive such medications during the screening period, or are anticipated to require such medications during the course of the study.
  10. Taking any investigational drug(s) or therapeutic device(s) within 30 days preceding screening
  11. History of radiation therapy of the affected foot
  12. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV
  13. Involved in a Worker's Compensation Claim of any kind
  14. Unable to understand the objectives of the trial
  15. Presence of any condition(s) which, in the opinion of the investigator, would compromise the subject's ability to complete this study
  16. Having a known history of poor adherence with medical treatment.
  17. Express an unwillingness to receive human allograft tissue

Sites / Locations

  • Advanced Orthopedics
  • Orlando Food and Ankle Clinic
  • The Iowa Clinic Foot and Ankle Surgery
  • Lower Extremity Institute of Research & Therapy (LEIRT)
  • Geisinger
  • The Vancouvover Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ReNu Injection

Corticosteroid Injection

Arm Description

Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

Plantar Fascia injection with Corticosteroids.

Outcomes

Primary Outcome Measures

Change in AOFAS score from baseline

Secondary Outcome Measures

Change in VAS pain score from baseline
Change in SANE function score from baseline
Return to Normal Function between treatment groups
Assessed using questionnaire by the Principal Investigator (PI)

Full Information

First Posted
November 29, 2016
Last Updated
April 17, 2020
Sponsor
NuTech Medical, Inc
Collaborators
MileStone Research Organization, Organogenesis
search

1. Study Identification

Unique Protocol Identification Number
NCT02982226
Brief Title
ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis
Official Title
A Comparative Study of Injectable Human Amniotic Allograft (ReNu™) Versus Corticosteroids for Plantar Fasciitis: A Prospective, Randomized, Blinded Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 2016 (Actual)
Primary Completion Date
April 2021 (Anticipated)
Study Completion Date
April 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NuTech Medical, Inc
Collaborators
MileStone Research Organization, Organogenesis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this clinical trial is to evaluate both the safety and efficacy of the ReNu™ injection on pain and inflammation in subjects diagnosed with plantar fasciitis as compared to a Corticosteroid Injection which is considered standard of care.
Detailed Description
This is a two (2) arm evaluation in 150 subjects with plantar fasciitis. Patients will be treated with ReNu™(study treatment) or Corticosteroids (control). At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete following questionnaires: AOFAS Ankle-Hindfoot Score (AOFAS-AHS) Visual Analog Score (VAS) Single Answer Numeric Evaluation (SANE) Subject Satisfaction Score (at the 6 Month Follow Ups ONLY) The subjects will be assessed at Baseline (pre-injection) using these scales and again at all subsequent study follow-up visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fasciitis, Plantar
Keywords
Plantar Fasciitis, Jogger's Heel, ReNu

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ReNu Injection
Arm Type
Experimental
Arm Description
Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Arm Title
Corticosteroid Injection
Arm Type
Active Comparator
Arm Description
Plantar Fascia injection with Corticosteroids.
Intervention Type
Other
Intervention Name(s)
ReNu Injection
Intervention Description
ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Intervention Type
Other
Intervention Name(s)
Corticosteroid Injection
Intervention Description
Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
Primary Outcome Measure Information:
Title
Change in AOFAS score from baseline
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Change in VAS pain score from baseline
Time Frame
6 months
Title
Change in SANE function score from baseline
Time Frame
6 months
Title
Return to Normal Function between treatment groups
Description
Assessed using questionnaire by the Principal Investigator (PI)
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 18 to 75 inclusive BMI less than 40 Actively practicing a contraception method, abstinent, surgically sterile, or post-menopausal (defined as no menses for a minimum of 12 months) Reporting heel pain of >6 on a verbally administered 1-10 pain scale where 1 is no pain and 10 is extreme pain Diagnosed with plantar fasciitis in either foot Completed a minimum of two months of conservative, non-injection treatment/therapies (i.e., activity modification, icing, NSAIDs, orthotics, physical therapy, etc.) Exclusion Criteria Prior surgery on the affected foot Prior injection treatment for plantar fasciitis within the past 6 months with steroids or tissue engineered materials just in the site seeking treatment Clinical signs and symptoms of infection of foot in question Evidence of significant neurological disease of either foot Non-ambulatory Presence of comorbidities that can be confused with or can exacerbate the condition including, but not limited to the following: Calcaneal stress fracture Nerve entrapment syndrome, such as Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome Plantar Fascial rupture Systemic disorders associated with enthesiopathy, i.e., Gout, Reiter's syndrome, rheumatoid arthritis, etc. Achilles tendonitis Fat Pad Atrophy Fibromyalgia Diabetic Neuropathy Pregnant, pregnant within the past six (6) months, breast feeding and/or desire to become pregnant during the course of the study, as verified by urine pregnancy test within one week prior to injection. Has taken NSAID medication within the past 14 days, or other pain medication in the past day History of more than two (2) weeks treatment with immuno-suppressants, including systemic corticosteroids or cytotoxic chemotherapy within one month prior to initial screening, or has receive such medications during the screening period, or are anticipated to require such medications during the course of the study. Taking any investigational drug(s) or therapeutic device(s) within 30 days preceding screening History of radiation therapy of the affected foot Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV Involved in a Worker's Compensation Claim of any kind Unable to understand the objectives of the trial Presence of any condition(s) which, in the opinion of the investigator, would compromise the subject's ability to complete this study Having a known history of poor adherence with medical treatment. Express an unwillingness to receive human allograft tissue
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alan Ng, DPM, FACFAS
Organizational Affiliation
Advanced Orthopedics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Advanced Orthopedics
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
Facility Name
Orlando Food and Ankle Clinic
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
The Iowa Clinic Foot and Ankle Surgery
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
Lower Extremity Institute of Research & Therapy (LEIRT)
City
Poland
State/Province
Ohio
ZIP/Postal Code
44514
Country
United States
Facility Name
Geisinger
City
Danville
State/Province
Pennsylvania
Country
United States
Facility Name
The Vancouvover Clinic
City
Vancouver
State/Province
Washington
ZIP/Postal Code
98686
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

We'll reach out to this number within 24 hrs